Second BZDS1901 milestone paid
Filed with ASX · · 4 pages · English
Earlier from AdAlta
- Regulatory advisors appointed for BZDS1901
- $2.5m placement
- BZDS1901 manufacturing agreement
- Automated cell therapy manufacturing MoU
- BZDS1901 clinical update
Later from AdAlta
- Oktopi AI collaboration for research efficiency
- 2 year survival milestone for EW-001 patient
- EW-001 IIT study overall survival update
- BZDS1901 special access scheme launch in China
- Oribiotech deal validates AdAlta manufacturing strategy
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta